A Global Asset Management Seoul Korea Magazine
Most Popular
The Rockefeller Foundation commits USD1 billion to catalyze a green recovery from pandemic
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- The Rockefeller Foundation will commit USD1 billion over the next three years to catalyze a more inclusive, green recovery from the COVID-19 pandemic. Building on current efforts and long-standing programs, the Foundation will focus on two key areas: catalyzing billions of dollars in private and concessional investments to scale distributed renewable energy across developing countries; and ensuring more equitable access to COVID-19 tests and vaccines, science-based tools, and data to fight the pandemic, while strengthening public health systems to prevent future outbreaks. In addition to this unique, one-time commitment of additional resources, The Rockefeller Foundation's efforts and energies, as a whole, will be rededicated and reoriented toward improving the lives of the world's poorest people and addressing inequities made worse by this virus. "There's no going back to the past, to before-COVID. We need to reimagine the future we want," said Dr. Rajiv J. Shah, President of the Rockefeller Foundation. "To meet this moment, we must leverage all our resources and relationships to build an equitable, sustainable future, where everyone has the opportunity to realize their full potential and climate disaster is avoided. The time to act is right now to make sure vulnerable
Victim describes abuse by Keith Raniere, leader of NXIVM sex cult
NEW YORK (NYTIMES) - Her voice trembling, the witness, identified only as Camila, recalled on Tuesday (Oct 27) the precise date that she was sexually abused by Keith Raniere, leader of a self-improvement company called NXIVM that prosecutors have described as a sex cult. It was Sept 18, 2005, she said in her victim statement. She was 15, and he was 45. He insisted, she said, that they both recognise the date as their anniversary. The relationship lasted 12 years, Camila said, with Raniere expecting her to be available for sex at all hours. He ordered her to weigh less than 45kg and directed her to get an abortion. She said she tried to kill herself once. "I want to move on, but he has damaged me in so many ways," said Camila, who added that she was still having trouble figuring out the line between an abusive and a normal relationship. Camila was the first of 15 victims who gave statements at Raniere's sentencing on Tuesday, where he was given 120 years, effectively life, in prison for sex trafficking and other crimes. Raniere, 60, had promised a path to happiness, seducing successful and wealthy
Belle Cosmic Manufacturing Presents Portable UV Disinfecting Cases for the Cosmetic Packaging Industry
HONG KONG, Oct. 28, 2020 /PRNewswire/ -- The coronavirus pandemic has made hygiene a topmost priority, with many people opting to carry a bottle of hand sanitizer with them so that they can disinfect their hands anytime, anywhere. Belle Cosmic Manufacturing Co. Ltd., Hong Kong, SAR China, has taken this safety measure up a notch by coming out with the Portable UV Disinfecting Cases for cosmetics products. Showcased during the Cosmoprof Asia Digital Week, these cosmetic cases uses ultraviolet C (UVC) light with a wavelength of 220-280 nanometers to kill 99% of germs in as little as five minutes. A study done by Hiroshima University researchers found that UVC light with a wavelength of 222 nanometers, which is safer to use around humans, effectively kills 99.7% of the SARS-CoV-2 viral culture after a 30-second exposure at 0.1 mW/cm2. The study is published in theAmerican Journal of Infection Control.* The 222 nm UVC light cannot penetrate the outer, non-living layer of the human eye and skin, as such it won't cause harm to the living cells beneath. This makes it a safer but equally potent alternative to the more damaging 254 nm UVC germicidal lamps used in disinfecting
GSK, Sanofi to make 200m doses available for Covid-19 vaccine alliance
PARIS (REUTERS) - French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their Covid-19 vaccine candidate available to the vaccine allocation plan co-led by Gavi and the World Health Organisation. The companies said on Wednesday (Oct 28) they have signed a statement of intent with vaccine alliance Gavi, which is coordinating the global plan known as Covax. Covax aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. GSK-Sanofi has currently signed a US$2.1 billion (S$2.8 billion) deal with the US to supply it with more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the European Union and UK. The first results from an early mid-stage study of the Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to file for regulatory approval in 2021. The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals
Quantum Genomics to receive up to $11.35 million in upfront and milestone payments plus double-digit royalties on sales Xediton Pharmaceuticals to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Canada PARIS and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics(Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Xediton Pharmaceuticals to develop and commercialize firibastat in Canada. Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada. Quantum Genomics has already recruited patients in Canada for the pivotal phase III study FRESH. Quantum Genomics will receive upfront and milestone payments amounting up to $11.35 million, plus double-digit royalties on sales. The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be between 1 and 1.5 million. “We are proud to partner firibastat with Xediton Pharmaceuticals, a private-held specialty Pharma. We share common values: positively impact the lives
